RBC Capital analyst Brian Abrahams raised the firm’s price target on PTC Therapeutics (PTCT) to $63 from $60 and keeps an Outperform rating on the shares. The firm’s survey of physician specialists indicates that given dissatisfaction with current PKU treatments, meaningful anticipated switches off Kuvan, and sustained use of brandeds in the space, the launch and long-term global sales opportunity for PTC’s sepiapterin should be substantial at about $700M, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- Roche announces FDA approves Evrysdi tablet to treat SMA
- PTC Therapeutics price target raised to $45 from $32 at Citi
- PTC Therapeutics price target raised to $113 from $76 at Cantor Fitzgerald
- PTC Therapeutics price target raised to $50 from $46 at TD Cowen
- PTC Therapeutics price target lowered at Cantor Fitzgerald, a top pick in 2025